PTM could not only effectively prevent the development of NAFLD in mice with a low dosage, but alleviate the severity of liver steatosis, by inhibiting the expression of FASN and related metabolic genes. This evidence concerns the gene FASN and metabolic dysfunction-associated steatotic liver disease.